Stock listing
Arch Biopartners, Inc.
Selected listing: 8HA · FWB · EUR · DE
Arch Biopartners, Inc. (Frankfurt:8HA), Health Technology. Latest release Aug 31, 2026: Arch Biopartners Receives Central IRB Approval to Support U.S. Sites…
- Ticker
- Frankfurt:8HA
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- Frankfurt
- Currency
- EUR
Latest news from Arch Biopartners, Inc.
Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide
August 31, 2026
Arch Biopartners to Expand Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial to the United States
August 11, 2026
Arch Biopartners Engages Private Laboratory to Accelerate IL-32 Chronic Kidney Disease Program
July 17, 2026
Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans
June 4, 2026
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
May 22, 2026
Research Arch Biopartners, Inc.
Arch Biopartners, Inc. company profile
View the public company page for Arch Biopartners, Inc. on 6ix.
Arch Biopartners, Inc. news
Read company news and market updates connected to Arch Biopartners, Inc..
Arch Biopartners, Inc. investor events
Find investor webinars, events, and replay context for Arch Biopartners, Inc..
Alternate listings
ARCH:TSXV
CA · CAD
Alternate listing for Arch Biopartners, Inc.; the primary context on this page is 8HA:FWB.
ARCH:NEO
CA · CAD
Alternate listing for Arch Biopartners, Inc.; the primary context on this page is 8HA:FWB.
ACHFF:OTC
US · USD
Alternate listing for Arch Biopartners, Inc.; the primary context on this page is 8HA:FWB.